Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of May 21, 2026, GENB trades at $13.25 with a market cap of $1.67B and a P/E ratio of -12.06. GENB moved +5.07% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $16.75. Analyst consensus is strong buy with an average price target of $25.40. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Generate Biomedicines Holds $516.6M Cash, Advances GB-0895 Phase 3 and GB-4362: Generate Biomedicines ended Q1 with $516.6 million in cash, cash equivalents and marketable securities, reflecting $369.3 million net IPO proceeds, and anticipates funding operations into H1 2028. The company advanced GB-0895 into Phase 3 asthma trials, activated GB-4362 sites for mid-2026 dosing and plans GB-5267 dosing in H2 2026.
| Metric | Value |
|---|---|
| Price | $13.25 |
| Market Cap | $1.67B |
| P/E Ratio | -12.06 |
| EPS | $-1.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.75 |
| 52-Week Low | $11.00 |
| Volume | 827.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.22M |
| Net Income | $-61.71M |
| Gross Margin | 0.00% |
6 analysts cover GENB: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.40.